Cell therapy biotech Longeveron sets terms for $25 million IPO - (NASDAQ via NewsPoints Desk)

  • Longeveron plans to raise $25 million in its initial public offering by offering 2.3 million shares at a price range of $10 to $12, as reported in NASDAQ.

  • The company’s lead product, LOMECEL-B, is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. 

  • Longeveron is currently sponsoring Phase I and II trials in aging frailty, Alzheimer’s disease, the metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

To read more NewsPoints articles, click here.